Korean J Gastroenterol.  2017 Oct;70(4):159-161. 10.4166/kjg.2017.70.4.159.

Usefulness of the Bravo Capsule pH Monitoring System in the Differential Diagnosis of Gastroesophageal Reflux Diseases

• Kim TH

• KMID: 2392910
• DOI: http://doi.org/10.4166/kjg.2017.70.4.159

Abstract

No abstract available.

MeSH Terms

Diagnosis, Differential*
Gastroesophageal Reflux*
Hydrogen-Ion Concentration*

Reference

1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005; 54:710–717.

2. Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil. 2011; 17:14–27.

3. Seo GS, Jeon BJ, Chung JS, et al. The prevalence of erosive esophagitis is not significantly increased in a healthy Korean population - could it be explained?: a multi-center prospective study. J Neurogastroenterol Motil. 2013; 19:70–77.

4. Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003; 98:1940–1944.

5. Chey WD, Mody RR, Wu EQ, et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin. 2009; 25:1869–1878.

6. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004; 2:656–664.

7. Hershcovici T, Fass R. Step-by-step management of refractory gastresophageal reflux disease. Dis Esophagus. 2013; 26:27–36.

8. Kondo T, Miwa H. The role of esophageal hypersensitivity in functional heartburn. J Clin Gastroenterol. 2017; 51:571–578.

9. Giacchino M, Savarino V, Savarino E. Distinction between patients with non-erosive reflux disease and functional heartburn. Ann Gastroenterol. 2013; 26:283–289.

10. Suzuki H. The application of the Rome IV criteria to functional esophagogastroduodenal disorders in Asia. J Neurogastroenterol Motil. 2017; 23:325–333.

11. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016. 02. 19. pii: S0016-5085(16)00223-7. [Epub ahead of print].

12. Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016; 51:751–767.

13. Frazzoni M, de Bortoli N, Frazzoni L, Tolone S, Savarino V, Savarino E. Impedance-pH monitoring for diagnosis of reflux disease: new perspectives. Dig Dis Sci. 2017; 62:1881–1889.

14. de Bortoli N, Martinucci I, Bertani L, et al. Esophageal testing: What we have so far. World J Gastrointest Pathophysiol. 2016; 7:72–85.

15. Wilson JA, Vela MF. New esophageal function testing (impedance, bravo pH monitoring, and high-resolution manometry): clinical relevance. Curr Gastroenterol Rep. 2008; 10:222–230.

16. Pandolfino J, Kwiatek M. Use and utility of the bravo pH capsule. J Clin Gastroenterol. 2008; 42:571–578.

17. Sofi AA, Filipiak C, Sodeman T, Ahmad U, Nawras A, Daboul I. Comparison of esophageal placement of bravo capsule system under direct endoscopic guidance with conventional placement method. Clin Exp Gastroenterol. 2010; 3:147–151.

18. Hirano I. Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease--bilitec, intraluminal impedance and bravo capsule pH monitoring. Aliment Pharmacol Ther. 2006; 23:Suppl 1. 12–24.

19. Kahrilas PJ, Pandolfino JE. Review article: oesophageal pH monitoring-- technologies, interpretation and correlation with clinical outcomes. Aliment Pharmacol Ther. 2005; 22:Suppl 3. 2–9.

20. Pandolfino JE. Bravo capsule pH monitoring. Am J Gastroenterol. 2005; 100:8–10.